Literature DB >> 16135994

Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women.

Boguslawa Baranowska1, Ewa Wolińska-Witort, L Martyńska, M Martyńska, Magdalena Chmielowska, Agnieszka Baranowska-Bik.   

Abstract

OBJECTIVE: It has been reported that the peptides such as orexins, neuropeptide Y (NPY) and leptin may play an important role in the regulation of appetite and energy metabolism. The interaction between leptin, orexins and NPY, as well as between peptides and insulin and cortisol in the different nutritional states have been investigated in animals. However, at present this relationship is poorly understood in humans. RESEARCH
METHODS: Material consisted of 36 obese women and 16 lean women. Plasma orexin A, orexin B, neuropeptide Y (NPY), leptin, insulin concentrations were measured with RIA methods.
RESULTS: Plasma orexin A concentrations were significantly lower in obese women as compared with control group. Plasma orexin A was significantly lower in severe obesity (BMI > 40 kg/m2) than that in moderate obesity (BMI < 40 kg/m2). Plasma orexin B concentrations did not change. However, plasma NPY, leptin and insulin levels were markedly higher in obese women, especially in severe obesity.
CONCLUSIONS: Our results confirmed the thesis that orexin A, NPY, leptin play an important role in the regulation of energy metabolism in humans. In obesity the activity of these peptides is disturbed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135994

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  26 in total

Review 1.  Obesity and chronic daily headache.

Authors:  Marcelo E Bigal; Alan M Rapoport
Journal:  Curr Pain Headache Rep       Date:  2012-02

Review 2.  Sleep and obesity: a focus on animal models.

Authors:  Vijayakumar Mavanji; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Neurosci Biobehav Rev       Date:  2012-01-16       Impact factor: 8.989

Review 3.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 4.  Migraine and obesity: epidemiology, possible mechanisms and the potential role of weight loss treatment.

Authors:  D S Bond; J Roth; J M Nash; R R Wing
Journal:  Obes Rev       Date:  2011-05       Impact factor: 9.213

5.  Orexin A regulates plasma insulin and leptin levels in a time-dependent manner following a glucose load in mice.

Authors:  Jae-Hyung Park; Hae-Min Shim; Ann-Yae Na; Jae-Hoon Bae; Seung-Soon Im; Dae-Kyu Song
Journal:  Diabetologia       Date:  2015-03-28       Impact factor: 10.122

6.  Detection of orexin A neuropeptide in biological fluids using a zinc oxide field effect transistor.

Authors:  Joshua Hagen; Wanda Lyon; Yaroslav Chushak; Melanie Tomczak; Rajesh Naik; Morley Stone; Nancy Kelley-Loughnane
Journal:  ACS Chem Neurosci       Date:  2013-01-22       Impact factor: 4.418

7.  Plasma orexin A levels in recently menopausal women during and 3 years following use of hormone therapy.

Authors:  Dahima Cintron; John P Beckman; Kent R Bailey; Brian D Lahr; Muthuvel Jayachandran; Virginia M Miller
Journal:  Maturitas       Date:  2017-02-17       Impact factor: 4.342

8.  Associations of plasma hypocretin-1 with metabolic and reproductive health: Two systematic reviews of clinical studies.

Authors:  Galit L Dunietz; Giancarlo Vanini; Carol Shannon; Louise M O'Brien; Ronald D Chervin
Journal:  Sleep Med Rev       Date:  2020-03-17       Impact factor: 11.609

9.  Regulation of adaptive behaviour during fasting by hypothalamic Foxa2.

Authors:  Jose P Silva; Ferdinand von Meyenn; Jessica Howell; Bernard Thorens; Christian Wolfrum; Markus Stoffel
Journal:  Nature       Date:  2009-12-03       Impact factor: 49.962

10.  Elevated sleep quality and orexin receptor mRNA in obesity-resistant rats.

Authors:  V Mavanji; J A Teske; C J Billington; C M Kotz
Journal:  Int J Obes (Lond)       Date:  2010-05-25       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.